In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Biogen trades significantly below its PERT-weighted fair value of $408.56, implying nearly 98% upside with high confidence. Despite fair financial health, low growth and profitability scores indicate operational risks. Monte Carlo results show extreme volatility but no downside scenarios below current price, suggesting high reward potential with elevated uncertainty.